ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag iron deficiency culture neuroscience

SYNGAP1 helps neurons eliminate old synapses and form new ones after a novel experience (left and center left)—a process weakened in mice missing a copy of the gene (center right and right).
Autism-Linked Gene SYNGAP1 Molds Synaptic Plasticity, Learning
Angie Voyles Askham, Spectrum | Oct 26, 2021 | 4 min read
The finding may help to explain why people with SYNGAP1 mutations tend to have learning difficulties and a high tolerance for pain.
T Cells and Neurons Talk to Each Other
Ashley Yeager | Oct 1, 2020 | 10+ min read
Conversations between the immune and central nervous systems are proving to be essential for the healthy social behavior, learning, and memory.
Immune System Maintains Brain Health
Amanda B. Keener | Nov 1, 2016 | 10+ min read
Once thought only to attack neurons, immune cells turn out to be vital for central nervous system function.
Top 10 Innovations 2013
The Scientist | Dec 1, 2013 | 10+ min read
The Scientist’s annual competition uncovered a bonanza of interesting technologies that made their way onto the market and into labs this year.
Alzheimer Research Joins the Mainstream
Christine Bahls | Jan 20, 2002 | 5 min read
In 1977, Alzheimer Disease researcher Peter Davies spoke with some neurologists about his work, which he began a year earlier. "One [neurologist] said, 'This is lovely..., but why don't you work on something that is more common?'" he remembers. Davies says the comment epitomized scientists' then-dismissive attitude about Alzheimer Disease (AD). When Alois Alzheimer first identified this memory-destroying disorder in 1907, his patient was a 50-year-old woman; a very early age, as researchers now
Clinical Trial Reversals Forcing Biotech Firms To Refine Strategy
Susan Dickinson | Sep 18, 1994 | 7 min read
Under pressure to reap return on investment, companies are seeking ways to ensure success in designing drug tests This past July, Synergen Inc. suspended clinical trials of its anti-inflammatory drug candidate, Antril--being tested to fight sepsis--for lack of efficacy. Faced with the setback to its $100 million-plus investment, the Boulder, Colo.-based biotech was forced to lay off more than half its work force and shut down two
Clinical Trial Reversals Forcing Biotech Firms To Refine Strategy
Susan Dickinson | Sep 18, 1994 | 7 min read
Under pressure to reap return on investment, companies are seeking ways to ensure success in designing drug tests This past July, Synergen Inc. suspended clinical trials of its anti-inflammatory drug candidate, Antril--being tested to fight sepsis--for lack of efficacy. Faced with the setback to its $100 million-plus investment, the Boulder, Colo.-based biotech was forced to lay off more than half its work force and shut down two
Scientists Can Help Keep The Media's Take On Research Closer To Reality
Ricki Lewis | Nov 24, 1996 | 7 min read
Being both a scientist by training and a journalist by practice gives one a unique perspective on the challenges of conveying science news to the public. Scientists can help writers and editors do their jobs without reducing every discovery to a potential cure for birth defects or cancer by learning to explain what they do, and how and why they do it, with both eloquence and excitement. A love of basic research drove me to both science and journalism. However, I left science shortly after earn
Ten Technologies in Five Years
Sam Jaffe(sjaffe@the-scientist.com) | Dec 5, 2004 | 8 min read
When scientists make long-term research plans, they must try to anticipate how emerging technologies will influence their work in the coming years.

Run a Search

ADVERTISEMENT